A 2018 review of sixteen scientific studies of cannabis-centered medicines for neuropathic pain, the majority of which tested a cannabinoid preparation referred to as nabiximols (brand name identify Sativex; a mouth spray containing the two THC and CBD which is approved in some countries but not in the United States), uncovered lower- to moderate-t